Differential Requirements for eIF4E Dose in Normal Development and Cancer - Wikidata - awgldk - TriplyDB

Differential Requirements for eIF4E Dose in Normal Development and Cancer

Differential Requirements for eIF4E Dose in Normal Development and Cancer

http://www.wikidata.org/entity/Q35816049

about

OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers Suppression Of β-catenin Nuclear Translocation By CGP57380 Decelerates Poor Progression And Potentiates Radiation-Induced Apoptosis in Nasopharyngeal Carcinoma.New frontiers in translational control of the cancer genome nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs GPRC5A suppresses protein synthesis at the endoplasmic reticulum to prevent radiation-induced lung tumorigenesis Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Regulation of Ribosome Biogenesis and Protein Synthesis Controls Germline Stem Cell Differentiation Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes Genomic analysis of the molecular neuropathology of tuberous sclerosis using a human stem cell model.CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.Rps26 directs mRNA-specific translation by recognition of Kozak sequence elements.Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasis Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer.Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.Identification of Fhit as a post-transcriptional effector of Thymidine Kinase 1 expression.Pharmacological eEF2K activation promotes cell death and inhibits cancer progression.MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmation.Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A.Proteome complexity and the forces that drive proteome imbalance.Developing anti-neoplastic biotherapeutics against eIF4F.The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions.Ribosomopathy-like properties of murine and human cancers.Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development.A novel function of cIAP1 as a mediator of CHIP-driven eIF4E regulation.A Cap for Every Occasion: Alternative eIF4F Complexes.A Transcript-Specific eIF3 Complex Mediates Global Translational Control of Energy Metabolism.Restoring microenvironmental redox and pH homeostasis inhibits neoplastic cell growth and migration: therapeutic efficacy of esomeprazole plus sulfasalazine on 3-MCA-induced sarcoma.Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E.

P2860

Q27728475-768724A8-B1BB-495A-B52F-378A80B39424 Q28829666-086ADBBB-73D4-4C6B-874C-36E507B327D9 Q33836444-2C1506C2-DC0E-43E6-969E-E78320ADD501 Q33853235-72C52A12-DEC1-4917-8A42-94CD57878C4C Q35960087-14BBB0A4-DF2D-4075-B0BB-BA4AC26B3387 Q36044216-19CC8084-A485-4532-ACE1-66F7167407BE Q36368265-697D2CB1-66DE-4480-B987-EA82FCCC5047 Q36378135-59F4EDF0-F642-47F0-8D8D-789AFAF73908 Q36390462-52D0439E-72F6-418D-94A2-3B383D2C3FC4 Q36545566-6A3B0974-42E8-424B-9FC7-32C5BD4998EC Q36552417-BA357D1B-03A5-47A0-BC17-E5E326833273 Q36596874-BF868398-09F0-4C6E-B51B-36F62C042F74 Q37046035-DE19CD34-6300-4EB2-B14D-7F725AE53A48 Q37272605-E920B65E-A507-4006-B659-EC4C12757810 Q37434173-72B47FCE-D0A8-4E8E-8232-177FD4924B31 Q37649874-EC63FFD3-092F-401B-8CD9-97BC1E52CB92 Q38290067-35F76A79-DAED-498B-9342-F84767036DE6 Q38429553-D8D4DDBF-375F-41B2-A909-296B8BC7F4F0 Q38628054-5645528B-CBB5-4CB9-87AA-38BB647751FD Q38637354-7D2A4DDC-747D-4E33-A5B6-E203A4477F7F Q38698803-F82DAF5C-D85A-4753-874D-D23195091F46 Q38717560-3D9E95EE-88E6-4108-A316-22DFCA0B7393 Q38721068-A2BB5876-C59C-45C5-ADF0-6C9EE3080B01 Q38749292-1244273E-4906-47EA-8AB0-2D4320C2CC3F Q38760569-5A644C7E-DA51-4EF2-9737-9B9E578553D4 Q38784326-135ECCC4-C776-4E75-B3F9-532F9BE2E042 Q38874189-026505F5-8D9A-41E6-940E-DB1BC00287E6 Q38954697-92BCCFAB-9BEF-4FAF-BED6-B6B048216B0D Q39048156-03CDCB7C-2343-498F-9031-3DE811E4AC2F Q39549442-3BEF74E6-3863-449A-BF81-8452F6E28EBF Q40078177-2065BBBE-215F-4D3F-8975-1B9AD4FAFF2E Q40974570-EC68AA4F-3A3E-4F3E-A381-A79B37834332 Q40975802-C4BCE119-3C8F-4572-94F0-BFE0BDB9161D Q41123932-55D08B5A-8680-4F39-B014-12935F73D7FC Q41549983-87E82F27-6ADA-45F1-97D9-D9128F18E24F Q41658238-320AA51E-958B-43AE-870B-40EB59A9ADB1 Q41698817-DEBBC06E-0983-4707-9976-EED27EE9FBE6 Q42366554-713DA53E-5657-46F4-BCC5-4C9FFB935EA3 Q42754623-6C7BAC0F-B283-4E98-B5C1-3DB53D7AE8DC Q44625005-F76D174E-A0FD-471A-BD0C-21F907912341

P2860

Differential Requirements for eIF4E Dose in Normal Development and Cancer

http://www.wikidata.org/entity/Q35816049

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Differential Requirements for eIF4E Dose in Normal Development and Cancer

@ast

Differential Requirements for eIF4E Dose in Normal Development and Cancer

@en

type

label

Differential Requirements for eIF4E Dose in Normal Development and Cancer

@ast

Differential Requirements for eIF4E Dose in Normal Development and Cancer

@en

prefLabel

Differential Requirements for eIF4E Dose in Normal Development and Cancer

@ast

Differential Requirements for eIF4E Dose in Normal Development and Cancer

@en

P1433

Q35816049-E5D13A09-5C17-487A-BB9B-5FFAD929F948

P1476

Q35816049-1AAAF7EB-488A-4842-A4C7-337B00815A01

P2093

Q35816049-0A4FF796-18DE-4BD1-B91C-9B14A916EFB8

Q35816049-15BFED80-78B7-4DD5-B35F-1B81263BF61F

Q35816049-33CFF9A7-9A06-4131-8250-5CBB388D12BF

Q35816049-B405A91E-10DB-4497-84FA-73CFBC5D1D49

Q35816049-BA1DFFD0-138D-4914-9BD7-EDF05FD9D0BB

Q35816049-BC5A2A34-F633-43EE-90BC-93FF3DB82F3E

Q35816049-C2762ADE-E8A8-41C0-AE97-7D6BECE1EF2E

Q35816049-CC2E6E72-D3FE-45C3-9188-49714828AB12

P2860

Q35816049-0B0899B6-C975-4A85-8903-A45788DA7FEB

Q35816049-24F9EC2C-3FAD-41E8-A7D1-35DB183B8271

Q35816049-2839C52D-A983-437A-A579-09DB0395EBCB

Q35816049-29C963D5-0CCA-49AB-AC61-3BF5D573250B

Q35816049-30F8903C-FE64-4755-875B-CFC1C8566E45

Q35816049-3302E612-02DE-4A5D-9427-8C15AED70B8A

Q35816049-3A1404AB-4566-4543-92A6-A866201993C9

Q35816049-44FF3EDB-CF91-49F6-A8CD-51D8B066101D

Q35816049-47E58114-74DF-43E0-A6B5-50887C983180

Q35816049-49EEAB4F-CA25-41A5-AC1E-2DA61915A01A

P304

Q35816049-A8E9B334-E3B0-4A00-9E96-89AAA8BB56FB

P31

Q35816049-C0E0216F-FA5B-4DCB-B857-081BCFCE6D0F

P356

Q35816049-2C97749B-9D3C-42E6-99F7-68118BE52BAD

P407

Q35816049-43FC1A07-E2C1-4329-8D3E-0F026CC92841

P433

Q35816049-ED8F944E-4F38-492E-BF1D-48978DC28D4A

P478

Q35816049-0B6D4400-A45A-4507-A60A-DD793785184F

P50

Q35816049-FFED996E-1CC5-4603-A887-654BDC879718

P577

Q35816049-4426AF4D-38A2-4B64-9E3B-107AD47EA3BC

P698

Q35816049-63A1E18B-6726-4563-A614-62F8A8C8CFF3

P932

Q35816049-479AD4AA-0B2E-4761-9CA8-404B00672E2A

P356

J.CELL.2015.05.049

P1433

P1476

Differential Requirements for eIF4E Dose in Normal Development and Cancer

@en

P2093

Alison M Coady

http://www.w3.org/2001/XMLSchema#string

Davide Ruggero

http://www.w3.org/2001/XMLSchema#string

Maria Barna

http://www.w3.org/2001/XMLSchema#string

Morgan L Truitt

http://www.w3.org/2001/XMLSchema#string

Taku Tokuyasu

http://www.w3.org/2001/XMLSchema#string

Xiaming Pang

http://www.w3.org/2001/XMLSchema#string

Youngho Seo

http://www.w3.org/2001/XMLSchema#string

Zhen Shi

http://www.w3.org/2001/XMLSchema#string

P2860

Translational homeostasis via the mRNA cap-binding protein, eIF4E

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E

RETRACTED: Selective killing of cancer cells by a small molecule targeting the stress response to ROS

Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch

eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

Glutathione synthesis is essential for mouse development but not for cell growth in culture

Mitochondria and cancer

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity

P304

59-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELL.2015.05.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

162

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26095252

http://www.w3.org/2001/XMLSchema#string

P932

4491046

http://www.w3.org/2001/XMLSchema#string